Abbott Laboratories stock falls after FDA approval
Published on 09/10/2026 at 16:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock (ISIN US0028241000) closed at USD 105.52 on the NYSE on September 9, 2026, after falling 2.6 percent, and it ended 2.9 percent below the 52-week high of USD 108.61.
FDA approval drives the move
Abbott Laboratories Inc. lost ground after the FDA approved its TactiFlex Duo Ablation Catheter, as ad hoc news reported on September 10, 2026. The same report said the stock also traded at 105.73 during the session, while the S&P 500 ended 0.48 percent lower at 7,636.36.
The price reaction came after a year in which Abbott's second quarter 2026 revenue reached USD 12.59 billion and EPS came in at USD 1.31, according to MarketBeat. MarketBeat also said that revenue rose 13.0 percent year over year and that EPS beat consensus by USD 0.03.
Analysts keep a constructive view
According to The Globe and Mail, Wells Fargo kept a Buy rating on Abbott Laboratories with a USD 112.00 price target in a report released yesterday, while the same report said the consensus target stands at USD 124.33. That leaves the stock 7.3 percent below the Wells Fargo target and 17.9 percent below the consensus level, based on the September 9 close.
For investors, the key number is the contrast between the FDA headline and the market's muted response. Abbott's Electrophysiology sales grew 13.4 percent in second-quarter 2026, and the stock still closed below its 52-week high.
Stock ends below high
Abbott Laboratories stock was last quoted at USD 105.52 on September 9, 2026, on the NYSE. The shares were 2.9 percent below the 52-week high of USD 108.61 and 5.6 percent above the 52-week low of USD 99.71.
Abbott Laboratories stock data
- Company: Abbott Laboratories Inc.
- ISIN: US0028241000
- Ticker: ABT
- Trading venue: NYSE
- Price (as of September 9, 2026): USD 105.52
- Sector / Industry: Health Care / Health Care Equipment & Supplies
- Index membership: S&P 500
